Novel opportunities for CFTR-targeting drug development using organoids

References

• Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992 - 2001; http://dx.doi.org/10.1056/NEJMra043184; PMID: 15888700
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066 - 73; http://dx.doi.org/10.1126/science.2475911; PMID: 2475911
   PubMed Web of Science ®Google Scholar
• Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 2000; 67:117 - 33; http://dx.doi.org/10.1159/000029497; PMID: 10773783
   PubMed Web of Science ®Google Scholar
• Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med 2012; 18:81 - 91; http://dx.doi.org/10.1016/j.molmed.2011.10.003; PMID: 22138491
   PubMed Web of Science ®Google Scholar
• Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7:201 - 4; http://dx.doi.org/10.1016/S1471-4914(01)01986-4; PMID: 11325631
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A 2009; 106:18825 - 30; http://dx.doi.org/10.1073/pnas.0904709106; PMID: 19846789
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al, VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663 - 72; http://dx.doi.org/10.1056/NEJMoa1105185; PMID: 22047557
   PubMed Web of Science ®Google Scholar
• Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67:12 - 8; http://dx.doi.org/10.1136/thoraxjnl-2011-200393; PMID: 21825083
   PubMed Web of Science ®Google Scholar
• Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012; 142:718 - 24; http://dx.doi.org/10.1378/chest.11-2672; PMID: 22383668
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011; 108:18843 - 8; http://dx.doi.org/10.1073/pnas.1105787108; PMID: 21976485
   PubMed Web of Science ®Google Scholar
• Roth EK, Hirtz S, Duerr J, Wenning D, Eichler I, Seydewitz HH, Amaral MD, Mall MA. The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS One 2011; 6:e24445; http://dx.doi.org/10.1371/journal.pone.0024445; PMID: 21909392
   PubMedGoogle Scholar
• Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tümmler B, Gallati S, Ballmann M. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010; 65:594 - 9; http://dx.doi.org/10.1136/thx.2009.125088; PMID: 20627915
   PubMed Web of Science ®Google Scholar
• Karp PH, Moninger TO, Weber SP, Nesselhauf TS, Launspach JL, Zabner J, Welsh MJ. An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures. Methods Mol Biol 2002; 188:115 - 37; PMID: 11987537
   PubMedGoogle Scholar
• Neuberger T, Burton B, Clark H, Van Goor F. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. Methods Mol Biol 2011; 741:39 - 54; http://dx.doi.org/10.1007/978-1-61779-117-8_4; PMID: 21594777
   PubMedGoogle Scholar
• Wong AP, Bear CE, Chin S, Pasceri P, Thompson TO, Huan LJ, Ratjen F, Ellis J, Rossant J. Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein. Nat Biotechnol 2012; 30:876 - 82; http://dx.doi.org/10.1038/nbt.2328; PMID: 22922672
   PubMed Web of Science ®Google Scholar
• Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell 2013; 13:149 - 59; http://dx.doi.org/10.1016/j.stem.2013.07.001; PMID: 23910082
   PubMed Web of Science ®Google Scholar
• Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 2013; 19:939 - 45; http://dx.doi.org/10.1038/nm.3201; PMID: 23727931
   PubMed Web of Science ®Google Scholar
• Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 2013; 340:1190 - 4; http://dx.doi.org/10.1126/science.1234852; PMID: 23744940
   PubMed Web of Science ®Google Scholar
• Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459:262 - 5; http://dx.doi.org/10.1038/nature07935; PMID: 19329995
   PubMed Web of Science ®Google Scholar
• Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 2011; 141:1762 - 72; http://dx.doi.org/10.1053/j.gastro.2011.07.050; PMID: 21889923
   PubMed Web of Science ®Google Scholar
• Tsui L-C. The spectrum of cystic fibrosis mutations. Trends Genet 1992; 8:392 - 8; PMID: 1279852
   PubMed Web of Science ®Google Scholar
• Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007; 175:1036 - 43; http://dx.doi.org/10.1164/rccm.200608-1164OC; PMID: 17332481
   PubMed Web of Science ®Google Scholar
• Weiller CA, Drumm ML. Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol 2013.
   Google Scholar
• Gan KH, Veeze HJ, van den Ouweland AM, Halley DJ, Scheffer H, van der Hout A, Overbeek SE, de Jongste JC, Bakker W, Heijerman HG. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995; 333:95 - 9; http://dx.doi.org/10.1056/NEJM199507133330204; PMID: 7539891
   PubMed Web of Science ®Google Scholar
• Cleveland RH, Zurakowski D, Slattery D, Colin AA. Cystic fibrosis genotype and assessing rates of decline in pulmonary status. Radiology 2009; 253:813 - 21; http://dx.doi.org/10.1148/radiol.2533090418; PMID: 19952026
   PubMed Web of Science ®Google Scholar
• Geborek A, Hjelte L. Association between genotype and pulmonary phenotype in cystic fibrosis patients with severe mutations. J Cyst Fibros 2011; 10:187 - 92; http://dx.doi.org/10.1016/j.jcf.2011.01.005; PMID: 21354377
   PubMed Web of Science ®Google Scholar
• Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 2013; 9:444 - 54; http://dx.doi.org/10.1038/nchembio.1253; PMID: 23666117
   PubMed Web of Science ®Google Scholar
• Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr., Urrutia A, Joubran J, Seepersaud S, Sussky K, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012; 11:237 - 45; http://dx.doi.org/10.1016/j.jcf.2011.12.005; PMID: 22293084
   PubMed Web of Science ®Google Scholar
• van Meegen MA, Terheggen-Lagro SWJ, Koymans KJ, van der Ent CK, Beekman JM. Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis. PLoS One 2013; 8:e57617; http://dx.doi.org/10.1371/journal.pone.0057617; PMID: 23483918
   PubMed Web of Science ®Google Scholar
• Penque D, Mendes F, Beck S, Farinha C, Pacheco P, Nogueira P, Lavinha J, Malhó R, Amaral MD. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest 2000; 80:857 - 68; http://dx.doi.org/10.1038/labinvest.3780090; PMID: 10879737
   PubMed Web of Science ®Google Scholar
• De Boeck K, Derichs N, Fajac I, de Jonge HR, Bronsveld I, Sermet I, Vermeulen F, Sheppard DN, Cuppens H, Hug M, et al, ECFS Diagnostic Network Working Group, EuroCareCF WP3 Group on CF diagnosis. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011; 10:Suppl 2 S53 - 66; http://dx.doi.org/10.1016/S1569-1993(11)60009-X; PMID: 21658643
   PubMed Web of Science ®Google Scholar
• Servidoni MF, Sousa M, Vinagre AM, Cardoso SR, Ribeiro MA, Meirelles LR, de Carvalho RB, Kunzelmann K, Ribeiro AF, Ribeiro JD, et al. Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility. BMC Gastroenterol 2013; 13:91; http://dx.doi.org/10.1186/1471-230X-13-91; PMID: 23688510
   PubMed Web of Science ®Google Scholar